Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Serial measurements of urinary hydroxyproline excretion were performed in 16 patients with stage D2 prostatic cancer to evaluate its role as a marker for following disease course. Patients were defined as having stable or progressive disease by the criteria of the National Prostatic Cancer Project. For patients with stable disease and those with disease progression excretion of hydroxyproline did not correlate with the clinical course. We did not find that hydroxyproline was a useful marker in the clinical setting to follow patients with prostatic cancer.
D001859:Bone Neoplasms / Q000556:secondary* / Q000652:urine; D002064:Buserelin / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D016729:Leuprolide; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000652:urine
D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D003404:Creatinine; D016729:Leuprolide; D002064:Buserelin; D006909:Hydroxyproline